News | Stents Drug Eluting | September 30, 2019

Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD

Results from the IDEAL-LM Study reported at TCT 2019

Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) is safe and effective in patients undergoing percutaneous coronary intervention (PCI) for unprotected left main coronary artery (uLMCA) disease. These findings are courtesy of the IDEAL-LM trial, which compared BP-EES plus four months of DAPT to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT.

Findings were reported at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Sept. 25-29 in San Francisco, sponsored by the Cardiovascular Research Foundation (CRF).

Continuous improvements in stent technology make PCI a potential alternative to surgery in selected patients with uLMCA disease. The optimal duration of DAPT in these patients after PCI remains undetermined and new stent designs using a bioabsorbable polymer may allow a shorter duration of DAPT.

IDEAL-LM is a prospective, randomized, multicenter study conducted at 29 sites in five countries. Between December 2014 and September 2016, a total of 818 patients were randomized 1:1 to BP-EES or to DP-EES. Procedural success was 99.9 percent, predominantly using single-stent techniques (79.6 percent). DAPT was stopped at four months in the BP-EES arm but continued for 12 months after PCI in the DP-EES arm. The primary endpoint assessment was a non-inferiority comparison of major adverse cardiovascular events (MACE) rate, including death from any cause, myocardial infarction or ischemia-driven target vessel revascularization (TVR) at two years after the procedure. Key secondary endpoints included ischemic and bleeding events.

The primary endpoint of non-inferiority for MACE at 24 months was met with 14.6 percent in the BP-EES group (n=403) compared to 11.4 percent in the DP-EES (n=396) group (p= 0.17). There were no differences in ischemic events, including no difference in stent thrombosis, between four and 12 months when the antiplatelet therapy was reduced in the BP-EES arm. However, this strategy did not result in a reduction of BARC 3 or 5 bleeding in the short DAPT group, with low-bleeding occurring in both study arms (2.7 percent for BP-EES versus 0.5 percent for DP-EES, p=0.02).

“IDEAL-LM confirms the excellent outcomes of current angioplasty techniques in patients with left main coronary artery disease,” said Prof. Robert-Jan Van Geuns, M.D., Ph.D., an interventional cardiologist at RadboudUMC, Nijmegen, The Netherlands and co-principal investigator of the study. “In addition, short DAPT is an option after angioplasty for left main disease with the latest DES design.” 

Prof. Keith G. Oldroyd of the Golden Jubilee National Hospital, the other co-principal investigator, commented that the somewhat surprising data on bleeding was likely due to the use of oral anticoagulation in some of the patients who bled and pointed out that the trial was not powered for bleeding events.

The IDEAL LM study was funded by Boston Scientific. The Golden Jubilee National Hospital, Glasgow, United Kingdom, served as sponsor. Van Geuns reports receiving speaker fees from Boston Scientific, Abbott Vascular and AstraZeneca. Oldroyd reports receiving speaker fees from Abbott Vascular and Biosensors and institutional research support from Boston Scientific.

More late-breaking coverage from TCT 2019

For more information: www.crt.org/tct

Related Content

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p